These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22732882)

  • 1. Residue-ligand interaction energy (ReLIE) on a receptor-dependent 3D-QSAR analysis of S- and NH-DABOs as non-nucleoside reverse transcriptase inhibitors.
    de Brito MA; Rodrigues CR; Cirino JJ; Araújo JQ; Honório T; Cabral LM; de Alencastro RB; Castro HC; Albuquerque MG
    Molecules; 2012 Jun; 17(7):7666-94. PubMed ID: 22732882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.
    Ragno R; Mai A; Sbardella G; Artico M; Massa S; Musiu C; Mura M; Marturana F; Cadeddu A; La Colla P
    J Med Chem; 2004 Feb; 47(4):928-34. PubMed ID: 14761194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D-QSAR CoMFA of a series of DABO derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors.
    de Brito MA; Rodrigues CR; Cirino JJ; de Alencastro RB; Castro HC; Albuquerque MG
    J Chem Inf Model; 2008 Aug; 48(8):1706-15. PubMed ID: 18671385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA.
    Xu HR; Fu L; Zhan P; Liu XY
    SAR QSAR Environ Res; 2016 Dec; 27(12):999-1014. PubMed ID: 27667445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
    Mao Y; Li Y; Hao M; Zhang S; Ai C
    J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Yu M; Fan E; Wu J; Liu X
    Curr Med Chem; 2011; 18(16):2376-85. PubMed ID: 21568919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Mai A; Sbardella G; Artico M; Ragno R; Massa S; Novellino E; Greco G; Lavecchia A; Musiu C; La Colla M; Murgioni C; La Colla P; Loddo R
    J Med Chem; 2001 Aug; 44(16):2544-54. PubMed ID: 11472208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
    Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
    J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docking field-based QSAR and pharmacophore studies on the substituted pyrimidine derivatives targeting HIV-1 reverse transcriptase.
    Fan N; Zhang S; Sheng T; Zhao L; Liu Z; Liu J; Wang X
    Chem Biol Drug Des; 2018 Feb; 91(2):398-407. PubMed ID: 28816417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
    Sivan SK; Manga V
    J Mol Model; 2010 Jun; 16(6):1169-78. PubMed ID: 20013136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of 3D-QSAR, Pharmacophore, and Molecular Docking in the Molecular Design of Diarylpyrimidine Derivatives as HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors.
    Liu G; Wang W; Wan Y; Ju X; Gu S
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.
    Hopkins AL; Ren J; Esnouf RM; Willcox BE; Jones EY; Ross C; Miyasaka T; Walker RT; Tanaka H; Stammers DK; Stuart DI
    J Med Chem; 1996 Apr; 39(8):1589-600. PubMed ID: 8648598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydro-alkoxyl-benzyl-oxopyrimidine derivatives (DABOs) as non-nucleoside reverse transcriptase inhibitors: an update review (2001-2011).
    Yang S; Chen FE; De Clercq E
    Curr Med Chem; 2012; 19(2):152-62. PubMed ID: 22320294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistant mechanism of diaryltriazine analog inhibitors of HIV-1 reverse transcriptase using molecular dynamics simulation and 3D-QSAR.
    Li Z; Zhang H; Li Y; Zhang J; Chen HF
    Chem Biol Drug Des; 2011 Jan; 77(1):63-74. PubMed ID: 21134218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docking-based 3D-QSAR and pharmacophore studies on diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Liu G; Wan Y; Wang W; Fang S; Gu S; Ju X
    Mol Divers; 2019 Feb; 23(1):107-121. PubMed ID: 30051344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of non nucleoside inhibitors with HIV-1 reverse transcriptase based on 3D-QSAR and docking.
    Chen HF; Yao XJ; Li Q; Yuan SG; Panaye A; Doucet JP; Fan BT
    SAR QSAR Environ Res; 2003; 14(5-6):455-74. PubMed ID: 14758988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach.
    Gussio R; Pattabiraman N; Zaharevitz DW; Kellogg GE; Topol IA; Rice WG; Schaeffer CA; Erickson JW; Burt SK
    J Med Chem; 1996 Apr; 39(8):1645-50. PubMed ID: 8648604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridine/Pyrimidine Substituted Imidazol-5-one Analogs as HIV-1 RT Inhibitors: Design, Synthesis, Docking and Molecular Dynamic Simulation Studies.
    Mokale S; Lokwani D; Mujaheed A
    Curr HIV Res; 2021; 19(6):535-547. PubMed ID: 34525923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.
    Jonckheere H; Taymans JM; Balzarini J; Velázquez S; Camarasa MJ; Desmyter J; De Clercq E; Anné J
    J Biol Chem; 1994 Oct; 269(41):25255-8. PubMed ID: 7523383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: SAR and Lead Optimization Using CoMFA and CoMSIA Studies (1995-2016).
    Vanangamudi M; Poongavanam V; Namasivayam V
    Curr Med Chem; 2017 Nov; 24(34):3774-3812. PubMed ID: 28685686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.